HFrEF stands for heart failure with reduced ejection fraction. It means the heart’s main pumping chamber, the left ventricle, has become too weak to push out a normal amount of blood with each beat. Specifically, a person is diagnosed with HFrEF when their ejection fraction, the percentage of blood the heart pumps out per beat, falls to 40% or below. A healthy heart typically ejects 50% to 70% of its blood with each contraction.
How Ejection Fraction Categories Work
Ejection fraction (EF) is the single most important number for classifying heart failure. It’s measured with an ultrasound of the heart called an echocardiogram. Current guidelines split heart failure into three categories based on this number:
- HFrEF (reduced): EF of 40% or lower
- HFmrEF (mildly reduced): EF of 41% to 49%
- HFpEF (preserved): EF of 50% or higher
The distinction matters because HFrEF has the strongest evidence base for specific medications that improve survival. HFpEF, by contrast, involves a heart that pumps adequately but stiffens and doesn’t fill properly, and it responds to a different treatment approach.
What Causes HFrEF
The most common cause is coronary heart disease, including heart attacks. When a section of heart muscle loses its blood supply during a heart attack, that tissue can die or become scarred, permanently weakening the heart’s pumping ability. Over time, the remaining healthy muscle compensates by working harder, but this extra strain can itself lead to further weakening.
Other causes include faulty heart valves that force the heart to pump against abnormal pressure, chronic irregular heart rhythms that gradually exhaust the muscle, and inherited or genetic heart diseases (cardiomyopathies) that cause the heart chambers to enlarge and weaken. Long-standing high blood pressure, heavy alcohol use, and certain chemotherapy drugs can also damage the heart enough to cause HFrEF.
What Happens Inside the Heart
When the heart’s pumping output drops, the body interprets it as a circulation problem and activates a stress response. The nervous system ramps up its “fight or flight” signaling, and the kidneys release hormones that constrict blood vessels and retain salt and water. In the short term, this keeps blood pressure up and organs supplied. Over weeks and months, though, these same compensatory systems backfire.
The sustained hormonal and nervous system overdrive causes the heart muscle to physically change, a process called remodeling. Heart muscle cells enlarge, the chamber walls stretch and thin, and scar tissue replaces healthy tissue. The heart literally changes shape, becoming rounder and larger. This remodeling further reduces pumping efficiency, creating a cycle where the body’s attempts to compensate make the underlying problem worse. Most HFrEF treatments work by interrupting this cycle.
Symptoms and Severity Classes
The hallmark symptoms of HFrEF are shortness of breath, fatigue, and fluid retention. Fluid can pool in the lungs (causing breathlessness, especially when lying flat), in the legs and ankles (causing swelling), or in the abdomen. Some people notice a persistent cough, rapid weight gain from fluid buildup, or feeling winded during activities they previously handled easily.
Doctors grade how much symptoms limit daily life using four functional classes:
- Class I: No limitations. Normal physical activity doesn’t cause unusual fatigue or shortness of breath.
- Class II: Slight limitation. Comfortable at rest, but ordinary activities like climbing stairs or carrying groceries cause fatigue or breathlessness.
- Class III: Marked limitation. Comfortable at rest, but even light activity like walking across a room triggers symptoms.
- Class IV: Symptoms at rest. Any physical activity increases discomfort.
A person’s class can shift over time. Effective treatment often moves someone from Class III to Class II, which translates to a meaningful improvement in quality of life.
How HFrEF Is Diagnosed
Diagnosis starts with an echocardiogram to measure ejection fraction. If the EF is 40% or below and symptoms of heart failure are present, the diagnosis is confirmed. Blood tests also play a role. A protein called NT-proBNP rises when the heart is under strain. Levels below 125 pg/mL generally make heart failure unlikely, while levels at or above 500 pg/mL strongly support the diagnosis (with a lower threshold of 220 pg/mL used for people with significant obesity, since fat tissue affects the marker).
Additional testing often follows to determine the cause. This might include stress testing, cardiac catheterization to check for blocked arteries, or cardiac MRI to look for scarring patterns that point to a specific type of cardiomyopathy.
The Four Pillars of Treatment
HFrEF has one of the most well-defined treatment strategies in cardiology, built around four complementary classes of medication that together reduce hospitalizations and extend life. These are often called the “four pillars” of therapy:
- Beta-blockers: Slow the heart rate and reduce the demand on the heart muscle, counteracting the overactive stress response.
- ARNI (angiotensin receptor-neprilysin inhibitors): Block harmful hormones while boosting the body’s own protective heart signals. These have largely replaced older medications called ACE inhibitors in current guidelines.
- MRAs (mineralocorticoid receptor antagonists): Block a hormone called aldosterone that drives fluid retention and heart scarring.
- SGLT2 inhibitors: Originally developed for diabetes, these reduce fluid overload and have shown striking benefits for heart failure regardless of whether a person has diabetes.
Current practice favors starting all four classes early and in parallel rather than adding them one at a time. Once started at low doses, each medication is gradually increased to target levels over weeks. Beyond these core drugs, some patients benefit from implantable devices like defibrillators (to prevent dangerous heart rhythms) or special pacemakers that coordinate the heart’s contractions.
Diet and Daily Management
Salt and fluid management are practical cornerstones of living with HFrEF. European guidelines recommend keeping salt intake below 5 grams per day (roughly one teaspoon). For context, the average Western diet easily exceeds this, often reaching 8 to 10 grams daily. Reading food labels and cooking at home are the most effective ways to stay within range.
Fluid intake generally falls between 1.5 and 2.5 liters per day for most people. Restricting below 1 to 1.5 liters is sometimes recommended during episodes of worsening fluid retention but isn’t standard for stable patients. Daily weigh-ins are one of the simplest monitoring tools: a gain of more than 2 to 3 pounds in a day, or 5 pounds in a week, often signals fluid buildup before other symptoms appear.
Regular physical activity, even moderate walking, improves exercise tolerance and quality of life in HFrEF. Cardiac rehabilitation programs provide structured, supervised exercise along with education on managing the condition day to day.
Outlook and What EF Changes Mean
HFrEF is a chronic condition, but it’s not necessarily a fixed one. With consistent use of guideline-directed medications, some people see their ejection fraction improve significantly, sometimes rising above 40% or even normalizing. When this happens, the condition is sometimes reclassified as “HF with improved EF.” This recovery reflects reverse remodeling, where the heart partially returns to its normal size and shape. Even when EF improves, continuing medications long-term is important because stopping them risks the heart weakening again.
Survival has improved substantially over the past two decades as treatments have advanced. The combination of all four medication classes, when tolerated, reduces the risk of cardiovascular death and hospitalization by a greater margin than any single drug alone. For people with advanced HFrEF who don’t respond to medication and devices, heart transplantation or mechanical heart pumps remain options.